HIMS vs. VRNA

Last updated Jun 9, 2026

HIMS (Hims & Hers Health, Inc.) and VRNA (Verona Pharma plc) are both stocks. HIMS operates in Household & Personal Products (Consumer Defensive), while VRNA operates in Biotechnology (Healthcare). At a 0.16 correlation, their price movements are largely independent.

Performance

HIMS vs. VRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Hims & Hers Health, Inc. (HIMS) and Verona Pharma plc (VRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

HIMS

• 1D: 3.74%
• 1M: -3.89%
• YTD: -16.32%
• 6M: -30.55%
• 1Y: -51.77%
• 3Y*: 44.53%
• 5Y*: 15.10%
• 10Y*: —

VRNA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

HIMS vs. VRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
HIMS Hims & Hers Health, Inc.	-16.32%	34.28%	171.69%	38.85%	-2.14%	-55.14%	47.47%	1.23%
VRNA Verona Pharma plc	0.00%	130.21%	133.60%	-23.92%	288.84%	-4.00%	21.74%	27.78%

Correlation

The correlation between HIMS and VRNA is 0.05, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.05
Correlation (3Y) Calculated over the trailing 3-year period	0.14
Correlation (5Y) Calculated over the trailing 5-year period	0.17
Correlation (All Time) Calculated using the full available price history since Sep 13, 2019	0.16

The correlation between HIMS and VRNA shifts across timeframes, from 0.05 (1 year) to 0.17 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap HIMS : $6.20B VRNA : $9.72B
EPS HIMS : -$0.05 VRNA : -$0.69
PS Ratio HIMS : 2.81 VRNA : 57.97
PB Ratio HIMS : 13.91 VRNA : 34.92
Total Revenue (TTM) HIMS : $2.37B VRNA : $167.65M
Gross Profit (TTM) HIMS : $1.70B VRNA : $159.52M
EBITDA (TTM) HIMS : $16.04M VRNA : -$40.86M

Return for Risk

HIMS vs. VRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

HIMS

HIMS Risk / Return Rank: 20
HIMS Sharpe Ratio Rank: 18
HIMS Sortino Ratio Rank: 22
HIMS Omega Ratio Rank: 23
HIMS Calmar Ratio Rank: 18
HIMS Martin Ratio Rank: 19

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

HIMS vs. VRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Hims & Hers Health, Inc. (HIMS) and Verona Pharma plc (VRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	HIMS	VRNA	Difference
Sharpe ratio: Return per unit of total volatility	-0.54	—	—
Sortino ratio: Return per unit of downside risk	-0.42	—	—
Omega ratio: Gain probability vs. loss probability	0.95	—	—
Calmar ratio: Return relative to maximum drawdown	-0.67	—	—
Martin ratio: Return relative to average drawdown	-1.09	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	HIMS	VRNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.54	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.18	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.21	—	—

Drawdowns

Drawdown Indicators

	HIMS	VRNA	Difference
Max Drawdown Largest peak-to-trough decline	-87.29%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-78.06%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-78.88%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-78.88%	—	—
Current Drawdown Current decline from peak	-60.47%	—	—
Average Drawdown Average peak-to-trough decline	-43.22%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	47.51%	—	—

Volatility

Volatility by Period

	HIMS	VRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	26.28%	—	—
Volatility (6M) Calculated over the trailing 6-month period	66.46%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	96.13%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	83.39%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	77.19%	—	—

Dividends

HIMS vs. VRNA - Dividend Comparison

Neither HIMS nor VRNA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

HIMS vs. VRNA - Profitability Comparison

The chart below illustrates the profitability comparison between Hims & Hers Health, Inc. and Verona Pharma plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

HIMS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Hims & Hers Health, Inc. reported a gross profit of 396.79M and revenue of 608.10M. Therefore, the gross margin over that period was 65.3%.

VRNA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.

HIMS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Hims & Hers Health, Inc. reported an operating income of -78.32M and revenue of 608.10M, resulting in an operating margin of -12.9%.

VRNA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.

HIMS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Hims & Hers Health, Inc. reported a net income of -92.12M and revenue of 608.10M, resulting in a net margin of -15.2%.

VRNA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.

Frequently Asked Questions

Can I hold both HIMS and VRNA in my portfolio?

HIMS and VRNA have a correlation of 0.05, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.